Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Blood Pressure-Lowering Property of Subcutaneous Semaglutide: A Systematic Review, Meta-Analysis, and Meta-Regression Publisher Pubmed



Ala M1 ; Moheb Aleaba M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Experimental Medicine Research Center, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Source: Journal of Endocrinological Investigation Published:2025


Abstract

Purpose: Semaglutide is a glucagon-like peptide (GLP1) receptor agonist with unprecedented weight-lowering and anti-hyperglycemic properties. Recent clinical trials reported that subcutaneous semaglutide can modulate blood pressure; however, its effect on blood pressure widely varied in different studies and different subgroups of patients. Methods: PubMed, Web of Science, Scopus, and the Cochrane Library were systematically searched from the inception to July 18, 2024. Due to high heterogeneity, a random-effects model was adopted to pool data. Results: Twenty clinical trials with 15,312 participants in the placebo group and 18,231 participants in the semaglutide group were included in this study. Subcutaneous semaglutide significantly decreased both systolic (WMD − 3.71 mmHg, 95% CI (-4.29, -3.13), I2: 50.2%) and diastolic (WMD − 1.10 mmHg, 95% CI (-1.58, -0.63), I2: 69.7%) blood pressure. Subgroup analyses indicated that the blood pressure-lowering property of subcutaneous semaglutide was greater among patients without diabetes, with lower baseline hemoglobin A1c (HbA1c), baseline body mass index (BMI) greater than 35 kg/m2, dose of semaglutide more than 1 mg/week, baseline systolic blood pressure equal or less than 130 mmHg, weight loss greater than 10 kg, and BMI reduction greater than 3 kg/m2. In addition, a treatment length of 50 to 100 weeks was associated with greater blood pressure-lowering effects in subgroup analysis. After adjusting for other factors, meta-regression revealed that placebo-adjusted weight change was independently correlated with the effect of semaglutide on systolic and diastolic blood pressure. Conclusion: Subcutaneous semaglutide can significantly decrease systolic and diastolic blood pressure, particularly in selected groups of patients. © The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE) 2024.
Related Docs
View other Related Docs
1. Suicide and Self-Harm Events With Glp-1 Receptor Agonists in Adults With Diabetes or Obesity a Systematic Review and Meta-Analysis, JAMA Psychiatry (2025)
2. Old and New Anti-Obesity Drugs, Journal of Diabetes and Metabolic Disorders (2025)
3. Weight Loss Breaks the Bond Between Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: A Clinical and Epidemiological Perspective, Obesity Reviews (2023)
4. The Effects of Subcutaneous Tirzepatide on Obesity and Overweight: A Systematic Review and Meta‐Regression Analysis of Randomized Controlled Trials, Frontiers in Endocrinology (2023)
5. Effect of L-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials, Advances in Nutrition (2022)
6. An Updated Systematic Review and Meta-Analysis on Portable Air Cleaners and Blood Pressure: Recommendations for Users and Manufacturers, Ecotoxicology and Environmental Safety (2023)
7. The Effects of L-Carnitine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-Analysis, Clinical Therapeutics (2024)
8. Prevalence, Awareness, Treatment, and Control of Hypertension Among Adult Residents of Tehran: The Tehran Cohort Study, Global Heart (2022)
Experts (# of related papers)
View all Related Experts
Kaveh Hosseini (2)
Khadijeh Mirzaei (1)
Other Related Docs
9. Population Attributable Fraction Estimates of Cardiovascular Diseases in Different Blood Pressure Levels in a Large-Scale Cross-Sectional Study: A Focus on Prevention Strategies and Treatment Coverage, Blood Pressure Monitoring (2023)
10. The Pathophysiological Associations Between Obesity, Nafld, and Atherosclerotic Cardiovascular Diseases, Hormone and Metabolic Research (2024)
11. Endocan As a Marker of Endothelial Dysfunction in Hypertension: A Systematic Review and Meta-Analysis, Hypertension Research (2023)
12. Neuropelveology for Endometriosis Management: A Systematic Review and Multilevel Meta-Analysis, Journal of Clinical Medicine (2024)
13. The Effect of Meal Replacements Therapy on Blood Pressure and C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Clinical Hypertension (2025)
14. Managing Cardiovascular Events, Hyperglycemia, and Obesity in Type 2 Diabetes Through Microrna Regulation Linked to Glucagon-Like Peptide-1 Receptor Agonists, Diabetology and Metabolic Syndrome (2025)
15. New Insights on the Predictive Value of Hypoperfusion Intensity Ratio in Thrombectomy: An Updated Systematic Review and Meta-Analysis With Multiple Cut-Offs, Journal of NeuroInterventional Surgery (2025)
16. The Cochrane Risk of Bias Assessment Tool 2 (Rob 2) Versus the Original Rob: A Perspective on the Pros and Cons, Health Science Reports (2024)
17. The Effect of Almond Intake on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Complementary Therapies in Medicine (2020)
18. Effect of Soluble Fiber on Blood Pressure in Adults: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials, Nutrition Journal (2023)
19. The Causal Effect of Family Physician Program on the Prevalence, Screening, Awareness, Treatment, and Control of Hypertension and Diabetes Mellitus in an Eastern Mediterranean Region: A Causal Difference-In-Differences Analysis, BMC Public Health (2023)
20. The Effect of Apple Cider Vinegar on Lipid Profiles and Glycemic Parameters: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, BMC Complementary Medicine and Therapies (2021)
21. Safety, Efficacy, and Cardiovascular Benefits of Combination Therapy With Sglt-2 Inhibitors and Glp-1 Receptor Agonists in Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Diabetology and Metabolic Syndrome (2025)
22. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2021)